» Articles » PMID: 18707795

Pathophysiological Roles of Osteoprotegerin (OPG)

Overview
Journal Eur J Cell Biol
Publisher Elsevier
Specialty Cell Biology
Date 2008 Aug 19
PMID 18707795
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoprotegerin (OPG) is a secreted glycoprotein central to bone turnover via its role as a decoy receptor for the receptor activator of nuclear factor kappaB ligand (RANKL) and has traditionally been linked to a number of bone-related diseases. However, there is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. As a result, a number of in vitro, in vivo and clinical studies have been performed assessing the role of OPG in tumourigenesis. Similar studies have been performed regarding vascular pathologies, resulting from observations of expression and regulation of OPG in the vasculature. This review aims to provide an update on this area and assess the potential protective or detrimental role of OPG in both vascular pathologies and tumourigenesis.

Citing Articles

RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.

Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F Int J Mol Sci. 2024; 25(17).

PMID: 39273141 PMC: 11395242. DOI: 10.3390/ijms25179193.


Molecular Pathways of Vulnerable Carotid Plaques at Risk of Ischemic Stroke: A Narrative Review.

Miceli G, Basso M, Pintus C, Pennacchio A, Cocciola E, Cuffaro M Int J Mol Sci. 2024; 25(8).

PMID: 38673936 PMC: 11050267. DOI: 10.3390/ijms25084351.


Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis.

Putri K, Adhyatmika A, Boorsma C, Habibie H, Ruigrok M, Heukels P Lung. 2024; 202(3):331-342.

PMID: 38642135 PMC: 11143060. DOI: 10.1007/s00408-024-00691-5.


Advanced applications of strontium-containing biomaterials in bone tissue engineering.

Sheng X, Li C, Wang Z, Xu Y, Sun Y, Zhang W Mater Today Bio. 2023; 20:100636.

PMID: 37441138 PMC: 10333686. DOI: 10.1016/j.mtbio.2023.100636.


Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.

Ma T, Zhao J, Yan Y, Liu J, Zang J, Zhang Y Front Cardiovasc Med. 2023; 10:1178153.

PMID: 37388640 PMC: 10300416. DOI: 10.3389/fcvm.2023.1178153.